Lawyers representing pharmaceutical companies in litigation over off-label marketing may want to read up on the U.S. Supreme Court’s decision in the so-called “Stolen Valor” case, former U.S. Solicitor General Paul Clement said Monday.

Clement was speaking to the Federalist Society in Philadelphia for his annual review of the high court’s term and noted there is one issue the court is often consistent on: First Amendment cases involving free speech.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]